The present study extends the recognized role of TRIM56 in antiviral innate immunity (15) and offers a potential pharmaceutical intervention strategy for NAFLD by targeting the TRIM56/FASN axis. This evidence concerns the gene TRIM56 and metabolic dysfunction-associated steatotic liver disease.